Literature DB >> 29177121

Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP).

Frederick S Kaplan1, Robert J Pignolo2, Mona M Al Mukaddam3, Eileen M Shore4.   

Abstract

Entities:  

Keywords:  ACVR1; Activin A; bone morphogenetic protein receptors; fibrodysplasia ossificans progressiva; heterotopic endochondral ossification; hypoxia

Year:  2017        PMID： 29177121      PMCID： PMC5697787          DOI： 10.1080/21678707.2017.1304211

Source DB:  PubMed          Journal:  Expert Opin Orphan Drugs        ISSN： 2167-8707            Impact factor:   0.694


× No keyword cloud information.
  17 in total

1.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

2.  Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.

Authors:  Devaveena Dey; Jana Bagarova; Sarah J Hatsell; Kelli A Armstrong; Lily Huang; Joerg Ermann; Ashley J Vonner; Yue Shen; Agustin H Mohedas; Arthur Lee; Elisabeth M W Eekhoff; Annelies van Schie; Marie B Demay; Charles Keller; Amy J Wagers; Aris N Economides; Paul B Yu
Journal:  Sci Transl Med       Date:  2016-11-23       Impact factor: 17.956

3.  Substance P signaling mediates BMP-dependent heterotopic ossification.

Authors:  Lixin Kan; Vitali Y Lounev; Robert J Pignolo; Lishu Duan; Yijie Liu; Stuart R Stock; Tammy L McGuire; Bao Lu; Norma P Gerard; Eileen M Shore; Frederick S Kaplan; John A Kessler
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

4.  An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.

Authors:  Salin A Chakkalakal; Deyu Zhang; Andria L Culbert; Michael R Convente; Robert J Caron; Alexander C Wright; Andrew D A Maidment; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

5.  Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Makoto Ikeya; Kazuhiko Horigome; Yoshihisa Matsumoto; Hayao Ebise; Megumi Nishio; Kazuya Sekiguchi; Mitsuaki Shibata; Sanae Nagata; Shuichi Matsuda; Junya Toguchida
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

6.  Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.

Authors:  Salin A Chakkalakal; Kenta Uchibe; Michael R Convente; Deyu Zhang; Aris N Economides; Frederick S Kaplan; Maurizio Pacifici; Masahiro Iwamoto; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2016-03-12       Impact factor: 6.741

7.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

8.  The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.

Authors:  Robert J Pignolo; Christopher Bedford-Gay; Moira Liljesthröm; Blythe P Durbin-Johnson; Eileen M Shore; David M Rocke; Frederick S Kaplan
Journal:  J Bone Miner Res       Date:  2015-11-14       Impact factor: 6.741

9.  Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.

Authors:  Haitao Wang; Carter Lindborg; Vitali Lounev; Jung-Hoon Kim; Ruth McCarrick-Walmsley; Meiqi Xu; Laura Mangiavini; Jay C Groppe; Eileen M Shore; Ernestina Schipani; Frederick S Kaplan; Robert J Pignolo
Journal:  J Bone Miner Res       Date:  2016-04-20       Impact factor: 6.741

Review 10.  Applications of small molecule BMP inhibitors in physiology and disease.

Authors:  Charles C Hong; Paul B Yu
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-14       Impact factor: 7.638
View more
  12 in total

Review 1.  Stem cells and heterotopic ossification: Lessons from animal models.

Authors:  John B Lees-Shepard; David J Goldhamer
Journal:  Bone       Date:  2018-01-31       Impact factor: 4.398

Review 2.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

Review 3.  Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification.

Authors:  Favour Felix-Ilemhenbhio; George A E Pickering; Endre Kiss-Toth; Jeremy Mark Wilkinson
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

4.  Clearance of Senescent Cells From Injured Muscle Abrogates Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.

Authors:  Haitao Wang; Qiang Zhang; Frederick S Kaplan; Robert J Pignolo
Journal:  J Bone Miner Res       Date:  2021-10-25       Impact factor: 6.390

Review 5.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

6.  Atypical Presentation of Fibrodysplasia Ossificans Progressiva: A Case Report and Review of Literature.

Authors:  Vivek Tiwari; Prateek Behera; Radha Sarawagi; Babu Mohammed Rafi; Saurabh Sahu; Hemanth Raj; Manish Rajpoot
Journal:  Cureus       Date:  2018-07-10

Review 7.  Targeting heterotopic ossification by inhibiting activin receptor‑like kinase 2 function (Review).

Authors:  Fuli Shi; Jiayu Gao; Junrong Zou; Ying Ying; Hui Lin
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

Review 8.  The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.

Authors:  Hui Lin; Fuli Shi; Jiayu Gao; Ping Hua
Journal:  Biosci Rep       Date:  2019-08-02       Impact factor: 3.840

Review 9.  Post-COVID-19 exacerbation of fibrodysplasia ossificans progressiva with multiple flare-ups and extensive heterotopic ossification in a 45-year-old female patient.

Authors:  Stela Hrkac; Grgur Salai; Lovorka Grgurevic; Rudjer Novak; Simeon Grazio
Journal:  Rheumatol Int       Date:  2021-06-10       Impact factor: 2.631

Review 10.  The Survey of Cells Responsible for Heterotopic Ossification Development in Skeletal Muscles-Human and Mouse Models.

Authors:  Łukasz Pulik; Bartosz Mierzejewski; Maria A Ciemerych; Edyta Brzóska; Paweł Łęgosz
Journal:  Cells       Date:  2020-05-26       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.